glp1 gip tirzepatide is a first-in-class dual agonist targeting both and GLP-1 receptors, offering a powerful and synergistic approach to glycaemic control and weight management., By acting on multiple In the SYNERGY-NASH trial, Tier:Restore (Advanced) bundle_menopause

glp1 gip tirzepatide is a first-in-class dual agonist targeting both and GLP-1 receptors, offering a powerful and synergistic approach to glycaemic control and weight management., By acting on multiple In the SYNERGY-NASH trial, Tier:Restore (Advanced) bundle_menopause

In the SYNERGY-NASH trial, researchers assessed the efficacy and safety of once-weekly tirzepatide in persons with metabolic dysfunction–associated steatohepatitis (MASH) and moderate or severe fibrosis. Full trial results and Plain Language Summary

2 In fact, all evaluated medications by the manufacturer, including ethinylestradiol and levonorgestrel, resulted in no dose adjustment recommendations

bundle_menopause

Tier:Restore (Advanced)

We track the research and will update patients as the evidence matures